Scientific American: New COVID Vaccines Need Absurd Amounts of Material and Labor

0 939

Before coronavirus hit, few people have heard of mRNA vaccines. Now with COVID-19 raging, companies are scrambling to produce them, pinning their hope on these vaccines. This is the first time that mRNA vaccines have been authorized for use outside a clinical trial. Under the Trump administration, a deal was reached between Pfizer in late December 2020 to supply 100 million doses to the U.S. Pfizer and its partner BioNTech plan to produce and distribute 1.3 billion doses globally next year. Despite the scientific breakthroughs, there are many limitations on manufacturing. Not a single facility in the world has manufactured mRNA vaccines at such a large scale before. Currently, Pfizer and Moderna have been building supply chains to increase production; however, each step of the manufacturing process requires raw materials that were only produced with clinical research in mind—the amount of raw material simply cannot sustain such large-scale manufacturing. For more information about COVID vaccines, click here. For the full article, click here.

Leave A Reply

Your email address will not be published.

Skip to toolbar